o2h discovery is excited to announce Ubiquigent as a winner of the o2h Kickstarter Competition. Ubiquigent Limited (Ubiquigent), a revenue- and IP-generating drug discovery company dedicated to enabling deubiquitinase (DUB)-focused drug discovery.
As part of the program, o2h discovery will provide Ubiquigent with access to chemists and associated end-to-end expertise to support its development of a novel portfolio of DUB-targeting compounds to enable the development of DUB-based therapeutics in partnership with its pharma and biotech partners.
The development of DUB-targeting compounds is…
• The top 20 global pharma companies, as a cohort, saw their combined R&D returns rise to 5.9% in 2024, up from 4.3% in 2023;
• GLP-1 drugs - which treat obesity and diabetes – are fuelling the surge, accounting for 2% of pharma’s forecast returns;
• Average cost to develop a drug has risen to $2.2 billion in 2024, up from $2.1 billion in 2023;
• 29 new ‘blockbuster assets’ (drugs with annual sales of at least $1 billion) have entered the drug development pipeline in 2024, up from 19 in 2023.
The return on investment in pharma research and development (R&D) has increased from the…
21 March 2025
Ahead of the long-awaited Industrial Strategy for life sciences, RSM UK calls on the government to address challenges around capital, talent and access to markets if the UK’s life sciences sector is to become an industry leader on the global stage.
The UK’s life sciences sector comprises over 6,800 businesses, generating more than £100bn in turnover in 2021/22. The sector relies heavily on the UK’s research and development (R&D) scheme as a form of funding, with the pharmaceutical industry accounting for 18% of all UK R&D in 2022 – the highest of any…
Cancer Research Horizons, the innovation arm of Cancer Research UK, launches the Cancer Impact Club, a community of business builders whose philanthropy, expertise and networks will help shape the future of cancer treatment. The club has recruited 13 members already, raising £1.3m of its £5m target.
Advances in biomedical understanding, technology and machine learning have brought us to the threshold of a golden age of scientific discovery. However, far too many potentially breakthrough innovations are lost in the funding gap between cutting-edge academic cancer research and a start-up…
On Friday 14 March, as part of a two-day visit to the East of England organised by Andrew Wood, Hon Dutch Consul for East Anglia with support from Norfolk County Council’s Inward Investment Team, Dutch Ambassador to the UK, Paul Huijts, visited scientists at some of the world-leading research institutes at Norwich Research Park.
After a networking lunch at which Nick Talbot, Executive Director and Group Leader of The Sainsbury Laboratory, provided the Ambassador with an overview of the park campus, Mr Huijts met with scientists at the leading edge of research into the role of the gut…
Oversubscribed financing led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund with M Ventures and Pfizer Ventures joining
Investment will support further development of CNS penetrant therapeutics based on the Company’s TRIMTACTM aggregate-selective degraders
Cambridge, UK, 05 March 2025: TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding round. The financing was led by Cambridge Innovation Capital (CIC…
• CDMO specialist signs long-term lease at Unity Campus• Unity Campus nears full occupancy with latest signing
Cambridge, 13th March 2025: Leading regional property investor and developer Howard Group, is delighted to announce a major new signing at its flagship science and technology hub Unity Campus.
Further strengthening South Cambridge’s growing bioscience cluster, Advent Bioservices has committed to a 5+5-year lease of lab and office space within the Cadence building, joining an impressive roster of life science innovators at the campus.The addition of Advent Bioservices means that…
London BioScience Innovation Centre welcomes Laverock Therapeutics to its newly completed fully fitted lab space within the Apex Building, Tribeca London- Laverock Therapeutics re-locates to LBIC to facilitate future growth, representing a key milestone for the company as it reports significant progress with its platform technologies, product pipeline and commercial offerings- Fit-out complete, Laverock Therapeutics is the first company to take up occupation within LBIC’s new grow-on lab space at Tribeca LondonLONDON, UK- 17th March 2025: London BioScience Innovation Centre (LBIC) is…
AMSBIO has launched GMP grade StemFit® for Differentiation - a chemically defined and animal component-free formulation that enables unmatched differentiation of human Induced Pluripotent Stem (hiPS) and Embryonic Stem (hES) cells. This medium now complies with Good Manufacturing Practices, as required for downstream clinical applications.
The unique chemically defined composition of StemFit® for Differentiation minimizes lot-to-lot variation, enabling highly consistent cell differentiation. The animal-origin free composition minimizes the risk of immunogenic contamination.…
3 July | Babraham Research Campus
Introducing ON Helix 2025ON Helix brings together key players in life sciences to explore critical themes shaping the journey from science to better patient outcomes. Through high quality presentations and panel discussions, ON Helix 2025 will discover and discuss the following themes:• Harnessing the Body’s Defences• Adoption of AI in Innovative Drug Discovery • Getting Ready for Clinic: Transformative Technologies• Invention,…